China Regenerative Medicine International Limited

As of June 30, 2024, China Regenerative Medicine International Limited carries a market capitalization of 50.20M, placing it among publicly traded companies globally. Its enterprise value stands at 99.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, China Regenerative Medicine International Limited has 304.25M shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, China Regenerative Medicine International Limited maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024.

As of the close on October 22, 2026, China Regenerative Medicine International Limited's stock has declined approximately 62.71% over the past 52 weeks. The 50-day moving average sits at 0.24, while the 200-day moving average is 0.41.

As of June 30, 2024, China Regenerative Medicine International Limited holds 1.85M in cash and equivalents against 50.88M in total debt, resulting in a net debt position of 39.37M. Total book value stands at 25.14M, with working capital of 34.66M providing operational flexibility.

China Regenerative Medicine International Limited's most recent stock split took place on September 22, 2023 with a 10:1 split ratio.